ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis The EXIT-SEP Randomized Clinical Trial

Liu, Songqiao; Yao, Chen; Xie, Jianfeng; Liu, Hong; Wang, Hongliang; Lin, Zhaofen; Qin, Bingyu; Wang, Difen; Lu, Weihua; Ma, Xiaochun; Liu, Yan; Liu, Ling; Zhang, Chi; Xu, Lei; Zheng, Ruiqiang; Zhou, Feihu; Liu, Zhongmin; Zhang, Guoqiang; Zhou, Lixin; Liu, Jian; Fei, Aihua; Zhang, Guoxiu; Zhu, Yimin; Qian, Kejian; Wang, Ruilan; Liang, Yafeng; Duan, Meili; Wu, Dawei; Sun, Rongqing; Wang, Ying; Zhang, Xijing; Cao, Quan; Yang, Mingshi; Jin, Minggen; Song, Yan; Huang, Ling; Zhou, Fachun佛山市第一人民医院; 复旦大学; 北京大学; 吉林大学; 南昌大学; 青岛大学; 上海交通大学; 兰州大学; 内蒙古医学院; 哈尔滨医科大学; 郑州大学; 武汉大学; 中国医科大学; 中国科学院; 1
JAMA Internal Medicine2023-7DOI: 10.1001/jamainternmed.2023.0780
9被引21阅读
引用收藏
分享

摘要

Importance Previous research has suggested that Xuebijing injection (XBJ), an herbal-based intravenous preparation, may reduce mortality among patients with sepsis.Objective To determine the effect of XBJ vs placebo on 28-day mortality among patients with sepsis.Design, Setting, and Participants The Efficacy of Xuebijing Injection in Patients With Sepsis (EXIT-SEP) trial was a multicenter, randomized double-blind, placebo-controlled trial conducted in intensive care units at 45 sites and included 1817 randomized patients with sepsis (sepsis 3.0) present for less than 48 hours. Patients aged 18 to 75 years with a Sequential Organ Failure Assessment score of 2 to 13 were enrolled. The study was conducted from October 2017 to June 2019. The final date of follow-up was July 26, 2019. Data analysis was performed from January 2020 to August 2022.Interventions The patients were randomized to receive either intravenous infusion of XBJ (100 mL, n = 911) or volume-matched saline placebo (n = 906) every 12 hours for 5 days.Main Outcomes and Measures The primary outcome was 28-day mortality.Results Among the 1817 patients who were randomized (mean [SD] age, 56.5 [13.5] years; 1199 [66.0%] men), 1760 (96.9%) completed the trial. In these patients, the 28-day mortality rate was significantly different between the placebo group and the XBJ group (230 of 882 patients [26.1%] vs 165 of 878 patients [18.8%], respectively; P < .001). The absolute risk difference was 7.3 (95% CI, 3.4-11.2) percentage points. The incidence of adverse events was 222 of 878 patients (25.3%) in the placebo group and 200 of 872 patients (22.9%) in the XBJ group.Conclusions and Relevance In this randomized clinical trial among patients with sepsis, the administration of XBJ reduced 28-day mortality compared with placebo.

学科与关键词

关键词
XUEBIJING INJECTIONINJURY
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
JAMA Internal Medicine
发表日期
2023-07
卷期
第 183 卷, 第 7 期
页码
647-655
DOI
10.1001/jamainternmed.2023.0780
语言
ENGLISH
成果收录
SCIE
资助标注
Development Center for Medical Science and Technology; National Health Commission of the People's Republic of China [WK-2016-HR-03]

作者

  • L

    Liu, Songqiao (第一作者)

    southeast univ

  • Y

    Yao, Chen

    1 · peking univ

查看全部 60 位作者收起作者
  • X

    Xie, Jianfeng

    southeast univ

  • L

    Liu, Hong

    1 · shanxi med univ

  • W

    Wang, Hongliang

    2 · harbin med univ

  • L

    Lin, Zhaofen

    changzheng hosp

  • Q

    Qin, Bingyu

    henan prov peoples hosp

  • W

    Wang, Difen

  • L

    Lu, Weihua

    1 · wannan med coll

  • M

    Ma, Xiaochun

    1 · china med univ

  • L

    Liu, Yan

    beijing univ chinese med

  • L

    Liu, Ling

    southeast univ

  • Z

    Zhang, Chi

    beijing univ chinese med

  • X

    Xu, Lei

    tianjin third cent hosp

  • Z

    Zheng, Ruiqiang

  • Z

    Zhou, Feihu

    chinese peoples liberat army gen hosp

  • L

    Liu, Zhongmin

    jilin univ

  • Z

    Zhang, Guoqiang

    china japan friendship hosp

  • Z

    Zhou, Lixin

    first peoples hosp foshan

  • L

    Liu, Jian

    1 · lanzhou univ

  • F

    Fei, Aihua

    shanghai jiao tong univ

  • Z

    Zhang, Guoxiu

    1

  • Z

    Zhu, Yimin

    hunan prov peoples hosp

  • Q

    Qian, Kejian

    1 · nanchang univ

  • W

    Wang, Ruilan

    shanghai jiao tong univ

  • L

    Liang, Yafeng

    qingdao univ · yantai yuhuangding hosp

  • D

    Duan, Meili

    capital med univ

  • W

    Wu, Dawei

    shandong univ

  • S

    Sun, Rongqing

    1 · zhengzhou univ

  • W

    Wang, Ying

    chinese pla gen hosp

  • Z

    Zhang, Xijing

  • C

    Cao, Quan

  • Y

    Yang, Mingshi

  • J

    Jin, Minggen

    yanbian univ hosp

  • S

    Song, Yan

    shenyang med coll

  • H

    Huang, Ling

  • Z

    Zhou, Fachun

    1 · chongqing med univ

  • C

    Chen, Dechang

    shanghai jiao tong univ

  • L

    Liang, Qun

    1 · heilongjiang univ chinese med

  • Q

    Qian, Chuanyun

    1 · kunming med univ

  • T

    Tang, Zhongzhi

    wuhan gen hosp

  • Z

    Zhang, Zhong

  • F

    Feng, Qiming

  • P

    Peng, Zhiyong

    wuhan univ

  • S

    Sun, Renhua

  • S

    Song, Zhenju

  • S

    Sun, Yunbo

  • C

    Chai, Yanfen

  • Z

    Zhou, Lihua

  • C

    Cheng, Chen

  • L

    Li, Li

  • Y

    Yan, Xiaoyan

    1 · peking univ

  • Z

    Zhang, Junhua

  • H

    Huang, Yingzi

    southeast univ

  • G

    Guo, Fengmei

    southeast univ

  • L

    Li, Chuan

  • Y

    Yang, Yi

    southeast univ

  • S

    Shang, Hongcai

    beijing univ chinese med

  • Q

    Qiu, Haibo

    southeast univ

  • E

    EXIT-SEP Investigators

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417